<DOC>
	<DOCNO>NCT01396512</DOCNO>
	<brief_summary>The purpose study compare Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine ( IMOJEV™ ) Japanese encephalitis live attenuate vaccine ( SA14 14 2 vaccine [ CD.JEVAX™ ] ) single dose vaccination support product registration . Primary Objective : - To demonstrate non-inferiority antibody response 28 day administration one dose IMOJEV™ compare antibody response 28 day administration one dose CD.JEVAX™ control vaccine . Secondary Objectives : - To describe immune response Japanese encephalitis ( JE ) vaccine group use 50 % plaque reduction neutralization assay ( PRNT50 ) assay single dose IMOJEV™ vaccine single dose CD.JEVAX™ vaccine . - To describe safety vaccination subject 28 day serious adverse event 6-month vaccination .</brief_summary>
	<brief_title>Study Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine ( IMOJEV™ ) Compared CD.JEVAX™ Toddlers</brief_title>
	<detailed_description>All participant receive single dose assign vaccination Visit 1 ( Day 0 ) undergo immunogenicity assessment Day 28 post-vaccination . Safety assess day vaccination 6 month post-vaccination .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 12 24 month day inclusion In good general health , without significant medical history . Provision informed consent form sign least one parent legally acceptable representative . Subject parent/guardian able attend schedule visit comply trial procedure . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination . Planned participation another clinical trial present trial period . Known suspect congenital acquire immunodeficiency , receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy . Known systemic hypersensitivity IMOJEV™ component history lifethreatening reaction vaccine contain substance vaccination , know systemic hypersensitivity CD.JEVAX® main component component ( include Gelatin , kanamycin , gentamicin ) . Chronic illness stage could interfere trial conduct completion , opinion Investigator . Receipt blood bloodderived product past 3 month , might interfere assessment immune response . Previous vaccination flavivirus disease , include Japanese encephalitis ( JE ) . Administration antiviral within 2 month precede Visit 01 4 week follow trial vaccination . Receipt vaccine 4 week precede first trial vaccination , except pandemic influenza vaccination , may receive least two week study vaccine . Planned receipt vaccine inclusion 4 week follow trial vaccination . History central nervous system disorder disease , include seizure . Planned receipt JE vaccine course study . History flavivirus infection ( confirm either clinically , serologically virologically ) . Administration systemic corticosteroid two consecutive week within 4 week precede vaccination . Febrile illness ( temperature ≥38.0°C ) moderate severe acute illness/infection 3 day vaccination well day vaccination , accord Investigator judgment . Thrombocytopenia bleed disorder contraindicate vaccination administration route , receipt anticoagulant 3 week precede inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>Japanese Encephalitis Virus Disease</keyword>
	<keyword>IMOJEV™</keyword>
	<keyword>CD.JEVAX™</keyword>
</DOC>